Cipla reported a significant decline in its consolidated net profit for the fourth quarter of the financial year 2025-26 (FY26), dropping 54.6% to ₹554.6 crore from ₹1,221.8 crore in the same quarter last year. Revenue from operations also fell by 2.8% to ₹6,541.2 crore. The downturn was primarily due to the absence of high-margin products like Lenalidomide and Landreotide, increased research and development (R&D) expenditures, and higher operational costs related to expanding its manufacturing capabilities in the United States. Despite these challenges, Cipla achieved its highest-ever annual revenue of ₹28,163 crore, reflecting a 2% year-on-year growth. Looking ahead, Cipla's management, led by Achin Gupta (managing director and global CEO), expressed optimism for FY27, forecasting EBITDA margins between 18.5% and 20% and a projected US business run-rate of $1 billion. The company plans to launch four respiratory products and one major peptide in FY27, while also managing geopolitical risks through inventory buffers and diversified sourcing. Cipla's India business showed resilience, growing 15% year-on-year to ₹3,007 crore in Q4, driven by strong sales in respiratory and cardiac therapies.